文献速递眼底病与葡萄膜炎

SGLT2抑制剂与DPP-4抑制剂使用及2型糖尿病患者年龄相关性黄斑变性:一项多国队列研究

Use of SGLT2 Inhibitors Versus DPP-4 Inhibitors and Age-Related Macular Degeneration in Patients WithType 2 Diabetes: A Multinational Cohort Study.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2025-01-01

这项多国回顾性队列研究纳入2013至2023年间21个国家医疗机构的50岁及以上2型糖尿病患者,比较SGLT2抑制剂与DPP-4抑制剂对年龄相关性黄斑变性风险的影响。经倾向评分1:1匹配后两组各20,966例,随访至多5年,SGLT2抑制剂组AMD风险显著低于DPP-4抑制剂组(HR 0.71,95%CI 0.58-0.85),干性AMD风险亦显著降低(HR 0.61,95%CI 0.46-0.80),湿性AMD无显著差异(HR 0.74,95%CI 0.48-1.16)。

要点

  • SGLT2抑制剂组AMD风险显著低于DPP-4抑制剂组(HR 0.71,95%CI 0.58-0.85)。
  • 干性AMD风险显著降低(HR 0.61,95%CI 0.46-0.80),湿性AMD无显著差异(HR 0.74,95%CI 0.48-1.16)。
  • 白人人群、使用恩格列净或达格列净者及糖化血红蛋白<8.5%等亚组中AMD风险降低。

核心结论

  • 在2型糖尿病患者中,与处方DPP-4抑制剂者相比,处方SGLT2抑制剂者可能具有更低的AMD和干性AMD风险。

研究设计与样本

  • 多国回顾性队列研究,使用21个国家医疗机构的电子病历数据。
  • 纳入50岁及以上、既往有二甲双胍处方且于2013至2023年间起始SGLT2或DPP-4抑制剂的2型糖尿病患者。
  • SGLT2抑制剂组与DPP-4抑制剂组按1:1倾向评分匹配,随访至多5年观察AMD发生。
  • 采用Cox比例风险模型和Kaplan-Meier分析进行统计分析。

主要发现

  • 最终分析纳入处方SGLT2抑制剂者20,966例和处方DPP-4抑制剂者20,966例。
  • 与DPP-4抑制剂组相比,SGLT2抑制剂组AMD风险显著降低(HR 0.71,95%CI 0.58-0.85)。
  • SGLT2抑制剂组干性AMD风险显著降低(HR 0.61,95%CI 0.46-0.80)。
  • SGLT2抑制剂组湿性AMD风险无显著差异(HR 0.74,95%CI 0.48-1.16)。
  • 在白人人群、处方恩格列净或达格列净者以及糖化血红蛋白<8.5%、估算肾小球滤过率≥60 mL/min/1.73 m2、高血压或血脂异常个体中,SGLT2抑制剂与AMD风险降低相关,且不受体重指数水平影响。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To compare the impact of sodium-glucose cotransporter 2 (SGLT2) and dipeptidyl peptidase 4 (DPP-4) inhibitors on age-related macular degeneration (AMD) risk among patients with type 2 diabetes mellitus (T2DM). METHODS: This multinational, retrospective cohort study used electronic medical records from healthcare institutions across 21 countries. Adults 50 years or older with T2DM who had a prior prescription of metformin and initiated SGLT2 or DPP-4 inhibitors from 2013 to 2023 were included. The SGLT2 and DPP-4 inhibitor groups were propensity score matched in a 1:1 ratio to balance baseline characteristics and were followed for up to 5 years to observe the occurrence of AMD. Statistical analysis was performed using the Cox proportional hazards model and Kaplan-Meier analysis. RESULTS: Our final analysis included 20,966 T2DM patients prescribed SGLT2 inhibitors and 20,966 prescribed DPP-4 inhibitors. Compared to the DPP-4 inhibitor group, the SGLT2 inhibitor group was associated with significantly lower risks of AMD (hazard ratio [HR], 0.71; 95% confidence interval [CI], 0.58-0.85) and dry AMD (HR, 0.61; 95% CI, 0.46-0.80) but not wet AMD (HR, 0.74; 95% CI, 0.48-1.16). SGLT2 inhibitors compared with DPP-4 inhibitors were linked to a reduced risk of AMD in the White population, patients prescribed empagliflozin or dapagliflozin, and individuals with glycated hemoglobin < 8.5%, estimated glomerular filtration rate ≥ 60 mL/min/1.73 m2, hypertension, or dyslipidemia, regardless of body mass index level. CONCLUSIONS: In patients with T2DM, those prescribed SGLT2 inhibitors may experience lower risks of AMD and dry AMD compared to those prescribed DPP-4 inhibitors.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Pan SY, Weng CH, Tsai SF, et al. Use of SGLT2 Inhibitors Versus DPP-4 Inhibitors and Age-Related Macular Degeneration in Patients WithType 2 Diabetes: A Multinational Cohort Study. Invest Ophthalmol Vis Sci. 2025. PMID: 40257783. doi:10.1167/iovs.66.4.58

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。